NIH Director’s Blog, 10 November 2015 In recent years, there’s been a lot of talk about…

American Diabetes Association Statement on Recent FDA Safety Changes in Labeling For Some Cholesterol-lowering Drugs

American Diabetes Association: Alexandria , VA – February 29, 2012.

Yesterday, the U.S. Food and Drug Administration (FDA) announced safety changes in the labeling for some cholesterol-lowering drugs (statins). According to the FDA’s safety announcement, the products include: Lipitor, Lescol, Mevacor, Altoprev, Livalo, Pravachol, Crestor and Zocor. Combination products include: Advicor, Simcor, and Vytorin.

In a statement, the FDA said, “Increases in blood sugar levels (hyperglycemia) have been reported with statin use. The FDA is also aware of studies showing that patients being treated with statins may have a small increased risk of increased blood sugar levels and of being diagnosed with type 2 diabetes mellitus.” Read More